NovoCure (STU:038) Total Operating Expense: €593.6 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:038 NovoCure Ltd STU:038
73 GF Score
Price €13.64
GF Value €16.39
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is NovoCure Total Operating Expense?

NovoCure STU:038 -3.23% 73 Total Operating Expense is €593.6 Mil as of Mar. 2026. GuruFocus rates STU:038 with a GF Score™ of 73/100 and a GF Value™ of €16.39 (Modestly Undervalued). The stock has 5 warning signs investors should review.

NovoCure's Total Operating Expense for the three months ended in Mar. 2026 was €175.2 Mil. NovoCure's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was €593.6 Mil.

NovoCure Total Operating Expense Related Terms

NovoCure Total Operating Expense Historical Data

* Premium members only.

The historical data trend for NovoCure's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NovoCure Total Operating Expense Chart

NovoCure Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 411.07 483.80 562.97 609.80 548.50

NovoCure Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 142.76 135.99 135.04 147.39 175.20
STU:038
73GF Score
NovoCure Ltd STU:038
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NovoCure Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €593.6 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of €593.6 Mil mean?
NovoCure (STU:038) has a Total Operating Expense of €593.6 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on NovoCure and its competitors.
Is NovoCure's Total Operating Expense too high?
NovoCure's current Total Operating Expense is €593.6 Mil. Overall, NovoCure has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does NovoCure's Total Operating Expense compare to ALMR and UFPT?
NovoCure's Total Operating Expense of €593.6 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Medical Devices & Instruments company?
A good Total Operating Expense depends on the Medical Devices & Instruments industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on NovoCure and its competitors. NovoCure's current Total Operating Expense is €593.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NovoCure stock overvalued right now?
Based on GuruFocus' analysis, NovoCure (STU:038) is currently considered Modestly Undervalued. The stock's GF Value™ is €16.39, compared to a current price of €13.64 — trading 16.8% below its estimated fair value. The current Total Operating Expense is €593.6 Mil. NovoCure's overall GF Score™ is 73/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For NovoCure (STU:038), the current Total Operating Expense is €593.6 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is NovoCure (STU:038) Overvalued in 2026?

Based on GuruFocus' analysis, NovoCure stock appears to be undervalued. The current stock price of €13.64 is trading 16.8% below its estimated GF Value™ of €16.39. GuruFocus considers NovoCure to be Modestly Undervalued.

Key valuation signals for STU:038:

  • Total Operating Expense: €593.6 Mil
  • GF Value™: €16.39 vs. price of €13.64 (16.8% below fair value)
  • GF Score™: 73/100 with 5 warning signs

No single metric tells the full story. See the STU:038 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

NovoCure Business Description

Address Grenville Street, No. 4 The Forum, Second Floor, St. Helier, JEY, JE2 4UF
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.
73GF Score

Get the complete analysis for STU:038

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€13.64
Price
€16.39
GF Value